2025 North America Antiviral Drugs Market Revenue Opportunities Report
Description
The 2025 North America Antiviral Drugs Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antiviral Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the North America Antiviral Drugs Market are Johnson & Johnson, Pfizer, Merck & Co., and AbbVie. Johnson & Johnson, through its pharmaceutical division Janssen, focuses on innovative antiviral treatments and conducts promising clinical studies such as those for dengue virus therapies. Pfizer strengthened its antiviral portfolio with acquisitions like ReViral, targeting respiratory syncytial virus (RSV), while continuing to lead with antivirals for COVID-19 and other infections. Merck & Co. emphasizes prescription medicines and vaccines addressing infectious diseases including viral infections. AbbVie holds a strong position through its significant performance in Hepatitis C antiviral therapies, notably with its drug MAVYRET, a direct-acting antiviral approved for both acute and chronic hepatitis C.
These companies benefit from extensive R&D and product portfolios covering HIV, hepatitis, influenza, and emerging viral diseases in North America, driving the market's growth projected to reach values over USD 21 billion. Gilead Sciences is also a key player noted for its antiviral agents like Biktarvy and Harvoni but ranks after the above four in terms of broad market presence. Collaborations, government support, and novel drug delivery systems further enhance competitiveness among these top firms in addressing increased viral disease prevalence and treatment innovation in the region.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antiviral Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the North America Antiviral Drugs Market are Johnson & Johnson, Pfizer, Merck & Co., and AbbVie. Johnson & Johnson, through its pharmaceutical division Janssen, focuses on innovative antiviral treatments and conducts promising clinical studies such as those for dengue virus therapies. Pfizer strengthened its antiviral portfolio with acquisitions like ReViral, targeting respiratory syncytial virus (RSV), while continuing to lead with antivirals for COVID-19 and other infections. Merck & Co. emphasizes prescription medicines and vaccines addressing infectious diseases including viral infections. AbbVie holds a strong position through its significant performance in Hepatitis C antiviral therapies, notably with its drug MAVYRET, a direct-acting antiviral approved for both acute and chronic hepatitis C.
These companies benefit from extensive R&D and product portfolios covering HIV, hepatitis, influenza, and emerging viral diseases in North America, driving the market's growth projected to reach values over USD 21 billion. Gilead Sciences is also a key player noted for its antiviral agents like Biktarvy and Harvoni but ranks after the above four in terms of broad market presence. Collaborations, government support, and novel drug delivery systems further enhance competitiveness among these top firms in addressing increased viral disease prevalence and treatment innovation in the region.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
